Salarius Pharmaceuticals Presents SP-3164 Preclinical Data at the Inaugural Molecular Glue Drug Development Summit

Posted: January 29, 2023 at 1:02 am

Preclinical data show synergistic activity for the targeted protein degrader SP-3164 with rituximab in non-Hodgkin’s lymphomas, and significantly better performance than standard-of-care treatment

Read the original post:
Salarius Pharmaceuticals Presents SP-3164 Preclinical Data at the Inaugural Molecular Glue Drug Development Summit

Related Posts